Advances in the investigation and treatment of pleural effusions

Expert Review of Respiratory Medicine

Volumn 4, Issue 1, 2010, Pages 123-133

  Mishra, Eleanor K ^a   Davies, Robert Jo ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Fibrinolytics; Indwelling pleural catheters; Malignant; Parapneumonic; Pleural effusion; Thoracoscopy; Ultrasound

Indexed keywords

ADENOSINE DEAMINASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; FIBRINOLYTIC AGENT; FLUORODEOXYGLUCOSE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESOTHELIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN; TALC; UROKINASE; VASCULOTROPIN;

ADVANCED CANCER; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CANCER STAGING; CHEMICAL ANALYSIS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DEVICE REMOVAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HEART FAILURE; HUMAN; INDWELLING CATHETER; INDWELLING PLEURAL CATHETER; LUNG SMALL CELL CANCER; NEOVASCULARIZATION (PATHOLOGY); PLEURA BIOPSY; PLEURA CANCER; PLEURA EFFUSION; PLEURA EMPYEMA; PLEURA FLUID; PLEURA METASTASIS; PLEURISY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; THORACOSCOPY; THORAX DRAINAGE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 77951642422     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.67     Document Type: Review

References (104)

1. Antony VB, Loddenkemper R, Astoul P et al. Management of malignant pleural effusions. Eur. Respir. J. 18(2), 402-419 (2001).
2. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 58(Suppl. 2), ii8-ii17 (2003).
3. Rahman NM, Davies RJO. Effusions from infections: parapneumonic effusion and empyema. In: Textbook of Pleural Diseases (2nd Edition). Light RW, Lee YCG (Eds). Oxford University Press, UK (2008).
4. Yap E, Anderson G, Donald J, Wong CA, Lee YC, Sivakumaran P. Pleural effusion in patients with pulmonary embolism. Respirology 13(6), 832-836 (2008).
5. Malignant mesothelioma mortality-United States, 1999-2005. MMWR Morb. Mortal. Wkly Rep. 58(15), 393-396 (2009).
6. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J. Thorac. Cardiovasc. Surg. 133(2), 346-351 (2007).
7. Roxburgh CS, Youngson GG. Childhood empyema in North-East Scotland over the past 15 years. Scott. Med. J. 52(4), 25-27 (2007).
8. Colice GL, Curtis A, Deslauriers J et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 118(4), 1158-1171 (2000).
9. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax 58(Suppl. 2), ii29-ii38 (2003).
10. Ferrer J, Roldan J, Teixidor J, Pallisa E, Gich I, Morell F. Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy. Chest 127(3), 1017-1022 (2005).
11. Porcel JM. Establishing a diagnosis of pleural effusion due to heart failure. Respirology 14(4), 471-473 (2009).
12. Jones PW, Moyers JP, Rogers JT, Rodriguez RM, Lee YC, Light RW Ultrasound-guided thoracentesis: is it a safer method? Chest 123(2), 418-423 (2003).
13. Duncan DR, Morgenthaler TI, Ryu JH, Daniels CE. Reducing iatrogenic risk in thoracentesis: establishing best practice via experiential training in a zero-risk environment. Chest 135(5), 1315-1320 (2009).
14. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 64(2), 139-143 (2009).
15. Mayo PH, Doelken P. Pleural ultrasonography. Clin. Chest Med. 27(2), 215-227 (2006).
16. Chian CF, Su WL, Soh LH, Yan HC, Perng WC, Wu CP. Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies. Chest 126(1), 129-134 (2004).
17. Duysinx B, Nguyen D, Louis R et al. Evaluation of pleural disease with 18-fuorodeoxyglucose positron emission tomography imaging. Chest 125(2), 489-493 (2004).
18. Orki A, Akin O, Tasci AE et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac. Cardiovasc. Surg. 57(4), 217-221 (2009).
19. Okutani D, Yamane M, Toyooka S et al. Dry small pleural dissemination of adenocarcinoma of the lung preoperatively detected by PET/CT: a report of two cases. Acta Med. Okayama 62(1), 55-58 (2008).
20. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 125(6), 2356-2360 (2004).
21. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl. Med. Commun. 27(12), 971-976 (2006).
22. Duysinx B, Corhay JL, Larock MP et al Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion. Nucl. Med. Commun. 29(11), 982-986 (2008).
23. Sahn SA, Good JT Jr. Pleural fuid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann. Intern. Med. 108(3), 345-349 (1988).
24. Rodriguez-Panadero F, Lopez Mejias J. Low glucose and pH levels in malignant pleural effusions. Diagnostic signifcance and prognostic value in respect to pleurodesis. Am. Rev. Respir. Dis. 139(3), 663-667 (1989).
25. Rahman NM, Mishra EK, Davies HE, Davies RJ, Lee YC. Clinically important factors infuencing the diagnostic measurement of pleural fuid pH and glucose. Am. J. Respir. Crit. Care Med. 178(5), 483-490 (2008).
26. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fuid chemical analysis in parapneumonic effusions. A meta-analysis. Am. J. Respir. Crit. Care Med. 151(6), 1700-1708 (1995).
27. Porcel JM, Vives M, Esquerda A, Ruiz A. Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. Respir. Med. 100(5), 933-937 (2006).
28. Porcel JM, Vives M, Cao G et al Biomarkers of infection for the differential diagnosis of pleural effusions. Eur. Respir. J. 34(6), 1383-1389 (2009).
29. Lin MC, Chen YC, Wu JT, Ko YC, Wang CC. Diagnostic and prognostic values of pleural fuid procalcitonin in parapneumonic pleural effusions. Chest 136(1), 205-211 (2009).
30. Liang QL, Shi HZ, Wang K, Qin SM, Qin XJ. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir. Med. 102(5), 744-754 (2008).
31. Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One 3(7), e2788 (2008).
32. Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ. Diagnostic value of interferon-y in tuberculous pleurisy: a metaanalysis. Chest 131(4), 1133-1141 (2007).
33. Hooper CE, Lee YC, Maskell NA. Interferon-y release assays for the diagnosis of TB pleural effusions: hype or real hope? Curr. Opin. Pulm. Med. 15(4), 358-365 (2009).
34. Chegou NN, Walzl G, Bolliger CT, Diacon AH, van den Heuvel MM. Evaluation of adapted whole-blood interferon-y release assays for the diagnosis of pleural tuberculosis. Respiration 76(2), 131-138 (2008).
35. Sack U, Hoffmann M, Zhao XJ et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur. Respir. J. 25(4), 600-604 (2005).
36. Sumi M, Kagohashi K, Satoh H, Ishikawa H, Funayama Y, Sekizawa K. Endostatin levels in exudative pleural effusions. Lung 181(6), 329-334 (2003).
37. Gaspar MJ, De Miguel J, Garcia Diaz JD, Diez M. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res. 28(5B), 2947-2952 (2008).
38. Vatansever S, Gelisgen R, Uzun H, Yurt S, Kosar F. Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions. Clin. Invest Med. 32(4), E293-E300 (2009).
39. Davies HE, Sadler RS, Bielsa S et al. Clinical impact and reliability of pleural fuid mesothelin in undiagnosed pleural effusions. Am. J. Respir. Crit. Care Med. 180(5), 437-444 (2009).
40. Creaney J, Yeoman D, Demelker Y et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J. Thorac. Oncol. 3(8), 851-857 (2008).
41. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 63(1), 35-41 (2008).
42. Bielsa S, Esquerda A, Salud A et al. High levels of tumor markers in pleural fuid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. Eur. J. Intern. Med. 20(4), 383-386 (2009).
43. Park EK, Sandrini A, Yates DH et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 178(8), 832-837 (2008).
44. Porcel JM, Martinez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fuid. Chest 136(3), 671-677 (2009).
45. Porcel JM, Chorda J, Cao G, Esquerda A, Ruiz-Gonzalez A, Vives M. Comparing serum and pleural fuid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient for the identifcation of cardiac effusions misclassifed by Light's criteria. Respirology 12(5), 654-659 (2007).
46. Kolditz M, Halank M, Schiemanck CS, Schmeisser A, Hoffken G. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur. Respir. J. 28(1), 144-150 (2006).
47. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 361(9366), 1326-1330 (2003).
48. Wilsher ML, Veale AG. Medical thoracoscopy in the diagnosis of unexplained pleural effusion. Respirology 3(2), 77-80 (1998).
49. Blanc FX, Atassi K, Bignon J, Housset B. Diagnostic value of medical thoracoscopy in pleural disease: a 6-year retrospective study. Chest 121(5), 1677-1683 (2002).
50. Bielsa S, Martin-Juan J, Porcel JM, Rodriguez-Panadero F. Diagnostic and prognostic implications of pleural adhesions in malignant effusions. J. Thorac. Oncol. 3(11), 1251-1256 (2008).
51. Breen D, Fraticelli A, Greillier L, Mallawathantri S, Astoul P. Redo medical thoracoscopy is feasible in patients with pleural diseases-a series. Interact. Cardiovasc. Thorac. Surg. 8(3), 330-333 (2009).
52. Sakuraba M, Masuda K, Hebisawa A, Sagara Y, Komatsu H. Thoracoscopic pleural biopsy for tuberculous pleurisy under local anesthesia. Ann. Thorac. Cardiovasc. Surg. 12(4), 245-248 (2006).
53. Yeo KT, Wang HH, Nagy JA et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and infammatory effusions. Cancer Res. 53(12), 2912-2918 (1993).
54. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol. Immunother. 48(7), 396-400 (1999).
55. Ishimoto O, Saijo Y, Narumi K et al. High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 63(1), 70-75 (2002).
56. Zebrowski BK, Yano S, Liu W et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. 5(11), 3364-3368 (1999).
57. Yano S, Shinohara H, Herbst RS et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. 157(6), 1893-1903 (2000).
58. Matsumori Y, Yano S, Goto H et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol. Res. 16(1), 15-26 (2006).
59. Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R. Diagnostic value of interleukine-6, transforming growth factor-b 1 and vascular endothelial growth factor in malignant pleural effusions. Respir. Med. 102(12), 1708-1714 (2008).
60. Cui R, Takahashi F, Ohashi R et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 63(3), 368-374 (2009).
61. Moschos C, Psallidas I, Kollintza A et al. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia 11(3), 298-304 (2009).
62. Stathopoulos GT, Psallidas I, Moustaki A et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J. Natl Cancer Inst. 100(20), 1464-1476 (2008).
63. Hoyer RJ, Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am. J. Hematol. 82(5), 409-413 (2007).
64. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N. Engl. J. Med. 353(7), 740-741 (2005).
65. Stathopoulos GT, Moschos C, Loutrari H et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am. J. Respir. Crit. Care Med. 178(1), 50-59 (2008).
66. Stathopoulos GT, Kollintza A, Moschos C et al. Tumor necrosis factor-a promotes malignant pleural effusion. Cancer Res. 67(20), 9825-9834 (2007).
67. Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology 7(3), 171-191 (2002).
68. Gjomarkaj M, Pace E, Melis M, Spatafora M, D'Amico D, Toews GB. Dendritic cells with a potent accessory activity are present in human exudative malignant pleural effusions. Eur. Respir. J. 10(3), 592-597 (1997).
69. Kitsuki H, Katano M, Ikubo A et al. Induction of infammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-g in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clin. Immunol. Immunopathol. 78(3), 283-290 (1996).
70. Yanagawa H, Haku T, Takeuchi E, Suzuki Y, Nokihara H, Sone S. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer. Lung Cancer 27(2), 67-73 (2000).
71. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am. J. Med. 63(5), 695-702 (1977).
72. Meyer PC. Metastatic carcinoma of the pleura. Thorax 21(5), 437-443 (1966).
73. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality signifcance. Am. J. Respir. Crit. Care Med. 174(7), 817-823 (2006).
74. Rahman NM, Maskell NA, Davies CW et al. 'The relationship between chest tube size and clinical outcome in pleural infection.' Chest (2009) (Epub ahead of print).
75. Maskell NA, Davies CW, Nunn AJ et al. UK controlled trial of intrapleural streptokinase for pleural infection. N. Engl. J. Med. 352(9), 865-874 (2005).
76. Cameron R, Davies HR. Intra-pleural fbrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst. Rev. 2, CD002312 (2008).
77. Thomson AH, Hull J, Kumar MR, Wallis C, Balfour Lynn IM. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 57(4), 343-347 (2002).
78. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest 111(6), 1548-1551 (1997).
79. Sonnappa S, Cohen G, Owens CM et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am. J. Respir. Crit. Care Med. 174(2), 221-227 (2006).
80. St Peter SD, Tsao K, Harrison C et al. Thoracoscopic decortication vs tube thoracostomy with fbrinolysis for empyema in children: a prospective, randomized trial. J. Pediatr. Surg. 44(1), 106-111; discussion 111 (2009).
81. Aziz A, Healey JM, Qureshi F et al. Comparative analysis of chest tube thoracostomy and video-assisted thoracoscopic surgery in empyema and parapneumonic effusion associated with pneumonia in children. Surg Infect. (Larchmt.) 9(3), 317-323 (2008).
82. Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients ft for pleurodesis. Eur. Respir. J. 30(4), 759-762 (2007). (Pubitemid 351194838)
83. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 129(2), 362-368 (2006).
84. Benabdallah BF, Bouchentouf M, Rousseau J et al. Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant. 17(3), 337-350 (2008).
85. Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest 131(4), 1232-1234 (2007).
86. Herlihy JP, Loyalka P, Gnananandh J et al. PleurX catheter for the management of refractory pleural effusions in congestive heart failure. Tex. Heart Inst. J. 36(1), 38-43 (2009).
87. Davies HE, Rahman NM, Parker RJ, Davies RJ. Use of indwelling pleural catheters for chronic pleural infection. Chest 133(2), 546-549 (2008).
88. Davies CW, Traill ZC, Gleeson F V, Davies RJ. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest 115(3), 729-733 (1999).
89. Hsu LH, Soong TC, Feng AC, Liu MC. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. J. Thorac. Oncol. 1(5), 460-467 (2006).
90. Dresler CM, Olak J, Herndon JE 2nd et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127(3), 909-915 (2005).
91. Paschoalini Mda S, Vargas FS, Marchi E et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 128(2), 684-689 (2005).
92. Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J. Surg. 28(8), 749-753; discussion 753-1744 (2004).
93. Das SK, Saha SK, Das A, Halder AK, Banerjee SN, Chakraborty M. A study of comparison of effcacy and safety of talc and povidone iodine for pleurodesis of malignant pleural effusions. J. Indian Med. Assoc. 106(9), 589-590, 592 (2008).
94. Maskell NA, Lee YC, Gleeson F V, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung infammation after pleurodesis with talc of varying particle size. Am. J. Respir. Crit. Care Med. 170(4), 377-382 (2004).
95. Stamatelopoulos A, Koullias G, Arnaouti M, Donta I, Perrea D, Dosios T. Malignant pleural effusion and talc pleurodesis. Experimental model regarding early kinetics of talc particle dissemination in the chest after experimental talc pleurodesis. J. BUON 14(3), 419-423 (2009).
96. Janssen JP, Collier G, Astoul P et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 369(9572), 1535-1539 (2007).
97. Terra RM, Junqueira JJ, Teixeira LR, Vargas FS, Pego-Fernandes PM, Jatene FB. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest 136(2), 361-368 (2009).
98. Rahman NM, Davies HE, Salzberg M et al. Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a Phase I toxicity and dose-escalation study. Lancet Oncol. 9(10), 946-952 (2008).
99. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifcation of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007). (Pubitemid 47357522)
100. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 111(6), 1710-1717 (1997).
101. Enatsu S, Yoshida J, Yokose T et al. Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients. Ann. Thorac. Surg. 81(1), 298-304 (2006). (Pubitemid 41815422)
102. Okada M, Sakamoto T, Nishio W, Uchino K, Tsuboshima K, Tsubota N. Pleural lavage cytology in non-small cell lung cancer: lessons from 1000 consecutive resections. J. Thorac. Cardiovasc. Surg. 126(6), 1911-1915 (2003).
103. Shepherd FA, Crowley J, Van Houtte P et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classifcation for lung cancer. J. Thorac. Oncol. 2(12), 1067-1077 (2007).
104. Ruffni E, Rena O, Bongiovanni M et al. The signifcance of intraoperative pleural effusion during surgery for bronchogenic carcinoma. Eur. J. Cardiothorac. Surg. 21(3), 508-513 (2002).